Colon cancer detection kit Typesen®
for endometrial cancergeneticfor PTEN gene

colon cancer detection kit
colon cancer detection kit
Add to favorites
Compare this product
 

Characteristics

Applications
colon cancer, for endometrial cancer
Tested parameter
EPCAM, PMS2, genetic, for PIK3CA Gene, for CTNNB1 gene, for MLH1 gene, for MSH2 gene, for MSH6 gene, for PTEN gene, for TP53 gene
Sample type
tissue
Analysis mode
molecular
Result display time

4 h

Description

Endometrial Carcinoma is the most common malignant tumor of the female reproductive system in developed countries.Factors related to endometrial cancer: 1. Obesity> 23kg of normal weight, the risk increases by 10 times; 2. Women who have not given birth and infertility;3. Patients with functional ovarian tumors (granulocytoma); 4. Long-term use of females hormones; 5. Genetic factors, family history of colon cancer (lynch syndrome). In 2013,The Cancer Genome Atlas (TCGA) studied 373 cases of Endometrial Carcinoma, Using genomics , transcriptomics and proteomics methods, by analyzing mutation spectrum, microsatellite instability (MSI), somatic cell copy Number changes (SCNAs), etc. TCGA divided Endometrial Carcinoma into four categories:(1)POLE ultramutated. (2) microsatellite instability-High(MSI-H) (3) copy number low(CN-L). (4)copy number high (CN-H). DETECTION ITEM The test kit detect 12 genes (POLE, TP53, MLH1, MSH2 , PMS2, MSH6, EPCAM, PTEN, KRAS, CTNNB1, PIK3CA, HER2) and MSI, related to the molecular classification of Endometrial Carcinoma. DETECTION SIGNIFICANCE POLE Ultramutated If the surgical stage is I/II,observation is preferred. MSI-H Intermediate prognosis, sensitive to treatment with immune checkpoint inhibitors, but current evidence is limited to advanced and recurrent cases. It is helpful for the screening of Lynch syndrome. Copy Number Low (CN-L) Intermediate prognosis, better outcomes in patients who recieved fertility-sparing therapy and are simultaneously with progesterone receptor–positive. Copy Number High (CN-H) Unfavorable prognosis, requires intensified adjuvant treatment, highly significant benefit from CTRT.

Catalogs

No catalogs are available for this product.

See all of SPACEGEN‘s catalogs
*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.